FDA approves ResMed vent for COPD patients

Thursday, April 25, 2013

SAN DIEGO – The Food and Drug Administration (FDA) has cleared ResMed’s variable positive airway pressure (VPAP) device for the treatment of COPD, according to a press release. The ResMed VPAP COPD, which will be sold in the United States, is designed to mitigate acute symptoms for COPD suffers, reducing hospital readmissions. “Minimizing the likelihood of acute events that lead to readmissions starts at the point of discharge, sending patients home with the best tools,” stated Geoff Neilson, president of ResMed’s respiratory care unit.